Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04211337
Title A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Eli Lilly and Company
Indications

thyroid gland medullary carcinoma

Therapies

Vandetanib

Cabozantinib

Selpercatinib

Age Groups: adult | senior | child
Covered Countries USA | CAN

Additional content available in CKB BOOST